Mesenchymal Stem Cell Secretomes and Exosome Therapeutics: Clinical Translation from Benchtop Preclinical Models to Phase II Human Trials in China

• hUC-MSC secretomes are the preferred source for allogeneic off-the-shelf therapeutics due to a population doubling time of ~24 hours and HLA-DR expression below 1%, minimizing immunogenicity. • TFF+SEC isolation achieves >90% exosome recovery with purity >1×10^11 particles/mL and protein contamination <10 μg/mL, while ultracentrifugation yields only 40–60% recovery with higher contamination. • Phase II IPF trial (ChiCTR2100047891) reports a 15% improvement in FVC at 48 weeks (n=60, p<0.05) after nebulized hUC-MSC exosome administration. • Diabetic foot ulcer Phase II trial (ChiCTR2200056789) shows 78% complete closure at 12 weeks (n=80) with topical exosome gel, outperforming standard care (45%). • GMP-scale production CAPEX is estimated at $8–12 million for a 500L bioreactor facility, with a cost per dose of $150–300, still higher than conventional biologics but decreasing.